OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Álex Bataller, Guillermo Montalban‐Bravo, Alexandre Bazinet, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 3, pp. e186-e195
Closed Access | Times Cited: 6
Álex Bataller, Guillermo Montalban‐Bravo, Alexandre Bazinet, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 3, pp. e186-e195
Closed Access | Times Cited: 6
Showing 6 citing articles:
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1563-1563
Open Access | Times Cited: 6
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1563-1563
Open Access | Times Cited: 6
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
Nishanth Thalambedu, Bhavesh Mohan Lal, Brent K. Harbaugh, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 508-508
Open Access
Nishanth Thalambedu, Bhavesh Mohan Lal, Brent K. Harbaugh, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 508-508
Open Access
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients
Pasquale Niscola
Expert Review of Hematology (2025)
Closed Access
Pasquale Niscola
Expert Review of Hematology (2025)
Closed Access
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study
Álex Bataller, Koji Sasaki, Samuel Urrutia, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Álex Bataller, Koji Sasaki, Samuel Urrutia, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Advances in the management of higher-risk myelodysplastic syndromes: future prospects
Georgina Gener‐Ricos, Juan José Rodríguez‐Sevilla, Samuel Urrutia, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 9, pp. 1233-1244
Closed Access
Georgina Gener‐Ricos, Juan José Rodríguez‐Sevilla, Samuel Urrutia, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 9, pp. 1233-1244
Closed Access
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, et al.
Annals of Hematology (2024)
Open Access
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, et al.
Annals of Hematology (2024)
Open Access
Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia
Sarit Assouline
The Lancet Haematology (2024) Vol. 11, Iss. 3, pp. e170-e171
Closed Access
Sarit Assouline
The Lancet Haematology (2024) Vol. 11, Iss. 3, pp. e170-e171
Closed Access
